(CRVS) Corvus Pharmaceuticals - NASDAQ
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 954m USD | Total Return: 157.8% in 12m
Avg Turnover: 18.8M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Share dilution 19.8% YoY
High Debt while negative Cash Flow
Interest Coverage Ratio -8.4 is critical
Below Avwap Earnings
Tailwinds
No distinct edge detected
Corvus Pharmaceuticals, Inc. (CRVS) is a clinical-stage biopharmaceutical firm based in South San Francisco, California. The company focuses on developing small molecules and antibodies designed to modulate immune cell maturation and function. Its primary therapeutic pipeline targets oncology, immunology, and inflammation through the inhibition of specific protein pathways.
The lead candidate, soquelitinib (CPI-818), is a selective covalent inhibitor of ITK currently undergoing Phase 1b/2 trials for peripheral T cell lymphoma and various autoimmune conditions. In the biotechnology sector, clinical-stage companies typically operate with high research and development expenses and rely on successful clinical trial transitions to reach commercialization. Corvus further diversifies its pipeline with ciforadenant (an A2A receptor antagonist) and mupadolimab (a monoclonal antibody), supported by strategic licensing agreements with institutions such as Monash University and Scripps.
To evaluate the long-term financial health and pipeline valuation of this firm, you may want to explore the detailed analytics available on ValueRay.
- Soquelitinib Phase 3 clinical trial results drive long-term valuation for T-cell lymphoma
- Pipeline expansion into immunology and atopic dermatitis markets creates new revenue streams
- Clinical stage status necessitates frequent equity financing through secondary stock offerings
- Regulatory approval timelines for lead candidate soquelitinib dictate near-term stock volatility
- Success of ciforadenant Phase 2 trials impacts oncology portfolio and partnership potential
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.14 > 0.02 and ΔFCF/TA 34.18 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.14 > 3% & CFO -34.9m > Net Income -44.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 19.81 > 1.5 & < 3 |
| Outstanding Shares: last quarter (90.0m) vs 12m ago 19.75% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.15%; Δ -0.15% > 0%) |
| Interest Coverage Ratio: -8.39 > 6 (EBIT TTM -47.5m / Interest Expense TTM 5.67m) |
| A: 0.90 (Total Current Assets 239.9m - Total Current Liabilities 12.1m) / Total Assets 253.2m |
| B: -1.68 (Retained Earnings -426.0m / Total Assets 253.2m) |
| C: -0.30 (EBIT TTM -47.5m / Avg Total Assets 156.3m) |
| D: 19.23 (Book Value of Equity 240.7m / Total Liabilities 12.5m) |
| Altman-Z'' = 18.57 = AAA |
As of June 12, 2026, the stock is trading at USD 11.60 with a total of 1,128,169 shares traded.
Over the past week, the price has changed by -1.02%,
over one month by -26.63%,
over three months by -31.36% and
over the past year by +157.78%.
Corvus Pharmaceuticals has received a consensus analysts rating of 4.83. Therefore, it is recommended to buy CRVS.
- StrongBuy: 5
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 33.3 | 187.3% |
P/B = 4.0985
Revenue TTM = 0.0 USD
EBIT TTM = -47.5m USD
EBITDA TTM = -47.4m USD
Long Term Debt = 406k USD (estimated: total debt 834k - short term 428k)
Short Term Debt = 428k USD (from shortTermDebt, last quarter)
Debt = 834k USD (from shortLongTermDebtTotal, last quarter) (leases 834k already included)
Net Debt = -235.9m USD (calculated: Debt 834k - CCE 236.7m)
Enterprise Value = 717.7m USD (953.6m + Debt 834k - CCE 236.7m)
Interest Coverage Ratio = -8.39 (Ebit TTM -47.5m / Interest Expense TTM 5.67m)
EV/FCF = -20.43x (Enterprise Value 717.7m / FCF TTM -35.1m)
FCF Yield = -4.90% (FCF TTM -35.1m / Enterprise Value 717.7m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 105k) / Revenue TTM)
Tobins Q-Ratio = 2.83 (Enterprise Value 717.7m / Total Assets 253.2m)
Interest Expense / Debt = 679.4% (Interest Expense 5.67m / Debt 834k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -37.6m (EBIT -47.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 19.81 (Total Current Assets 239.9m / Total Current Liabilities 12.1m)
Debt / Equity = 0.00 (Debt 834k / totalStockholderEquity, last quarter 240.7m)
Debt / EBITDA = 4.97 (negative EBITDA) (Net Debt -235.9m / EBITDA -47.4m)
Debt / FCF = 6.71 (negative FCF - burning cash) (Net Debt -235.9m / FCF TTM -35.1m)
Total Stockholder Equity = 113.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -28.26% (Net Income -44.2m / Total Assets 253.2m)
RoE = -38.92% (Net Income TTM -44.2m / Total Stockholder Equity 113.5m)
RoCE = -41.75% (EBIT -47.5m / Capital Employed (Equity 113.5m + L.T.Debt 406k))
RoIC = -15.55% (negative operating profit) (NOPAT -37.6m / Invested Capital 241.5m)
WACC = 7.35% (E(953.6m)/V(954.4m) * Re(7.36%) + (debt cost/tax rate unavailable))
Discount Rate = 7.36% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.39 | Cagr: 30.98%
[DCF] Fair Price = unknown (Cash Flow -35.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.09 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.17 | Chg30d=+1.45% | Revisions=-43% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.19 | Chg30d=+3.80% | Revisions=-43% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.72 | Chg30d=+4.12% | Revisions=-43% | GrowthEPS=-33.4% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.95 | Chg30d=-12.37% | Revisions=-43% | GrowthEPS=-32.1% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -43%